Particularly, women harboring BRCA1/2-mutated ovarian cancers exhibit both enhanced response to platinum-based chemotherapeutic regimens and significantly improved OS when compared with patients diagnosed with non-BRCA-mutated tumors; captivatingly, these effects are more prominent for BRCA2 mutation carriers, who show even longer survival with respect to BRCA1 patients [18,19,20]. This evidence concerns the gene BRCA2 and ovarian carcinoma.